GDOC stock forecast, quote, news & analysis

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX), ZOETIS (NYSE:ZTS), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Biogen (NASDAQ:BIIB).

The investment seeks long-term growth of capital. The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non‑U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.

The average market capitalization across the Goldman Sachs Future Health Care Eq ETF ETF is 59.65B. The market cap for tickers in the group ranges from 1.43B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is DYN at 1.43B.

The average weekly price growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was 7%. For the same ETF, the average monthly price growth was 16%, and the average quarterly price growth was 73%. STVN experienced the highest price growth at 7%, while COO experienced the biggest fall at -5%.

The average weekly volume growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was -18%. For the same stocks of the ETF, the average monthly volume growth was -10% and the average quarterly volume growth was 61%